{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,11]],"date-time":"2026-10-11T12:35:52Z","timestamp":1791722152996,"version":"4.3.4"},"reference-count":63,"publisher":"MDPI AG","issue":"8","license":[{"start":{"date-parts":[[2025,8,15]],"date-time":"2025-08-15T00:00:00Z","timestamp":1755216000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Biomolecules"],"abstract":"<jats:p>Background: Atrial fibrillation (AF) is common complication of heart failure with preserved ejection fraction (HFpEF) that sufficiently intervenes in the prognosis. The aim of the study is a) to investigate the possible discriminative value of adropin for newly onset AF in patients with HFpEF without a previous history of AF and who are being treated in accordance with conventional guideline and b) to compare it with predictive potencies of conventionally used predictors. Methods: A total of 953 patients with HFpEF who had sinus rhythm on ECG were enrolled in the study. The course of the observation was 3 years. Echocardiography and assessment of conventional hematological, biochemical parameters and biomarker assay including N-terminal brain natriuretic pro-peptide (NT-proBNP), high-sensitivity cardiac troponin T, tumor necrosis factor-alpha, high-sensitivity C-reactive protein (hs-CRP), galectin-3, interleukin-6, soluble suppressor tumorigenisity-2 (sST2) and adropin, were performed at baseline. Results: Incident atrial fibrillation was found in 172 patients with HFpEF, whereas 781 had sinus rhythm. In unadjusted rough Cox regression model, age \u2265 75 years, type 2 diabetes mellitus, chronic kidney disease (CKD) stages 1\u20133, left atrial volume index (LAVI) \u2265 40 mL\/m2, NT-proBNP \u2265 1440 pmol\/mL, hs-CRP \u2265 5.40 mg\/L, adropin \u2264 2.95 ng\/mL, sST2 \u2265 15.5 ng\/mL were identified as the predictors for new onset AF in HFpEF patients. After adjusting for age \u2265 75 years, a presence of type 2 diabetes mellitus and CKD stages 1\u20133, the levels of NT-proBNP \u2265 1440 pmol\/mL and adropin \u2264 2.95 ng\/mL were independent predictors of new onset AF in patients HFpEF. We also found that discriminative value of adropin was superior to NT-proBNP, while adding adropin to NT-proBNP did not improve predictive information of adropin alone. Conclusions: adropin \u2264 2.95 ng\/mL presented more predictive information than NT-proBNP \u2265 1440 pmol\/mL alone for new cases of AF in symptomatic patients with HFpEF, whereas the combination of both biomarkers did not improve the predictive ability of adropin alone.<\/jats:p>","DOI":"10.3390\/biom15081171","type":"journal-article","created":{"date-parts":[[2025,8,15]],"date-time":"2025-08-15T14:24:28Z","timestamp":1755267868000},"page":"1171","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Low Levels of Adropin Predicted New Incidents of Atrial Fibrillation in Patients with Heart Failure with Preserved Ejection Fraction"],"prefix":"10.3390","volume":"15","author":[{"given":"Tetiana A.","family":"Berezina","sequence":"first","affiliation":[{"name":"Department of Internal Medicine and Nephrology, VitaCenter, 69000 Zaporozhye, Ukraine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oleksandr O.","family":"Berezin","sequence":"additional","affiliation":[{"name":"Luzerner Psychiatrie AG, 4915 St. Urban, 6110 Wolhusen, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5864-0604","authenticated-orcid":false,"given":"Evgen V.","family":"Novikov","sequence":"additional","affiliation":[{"name":"Department of Functional Diagnostics, Shupyk National Healthcare University of Ukraine, 04136 Kyiv, Ukraine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0446-3999","authenticated-orcid":false,"given":"Alexander E.","family":"Berezin","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine II, Division of Cardiology, Paracelsus Medical University, 5020 Salzburg, Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2025,8,15]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","unstructured":"Sagris, M., Vardas, E.P., Theofilis, P., Antonopoulos, A.S., Oikonomou, E., and Tousoulis, D. (2021). Atrial Fibrillation: Pathogenesis, Predisposing Factors, and Genetics. Int. J. Mol. Sci., 23.","DOI":"10.3390\/ijms23010006"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"1933","DOI":"10.1007\/s10741-021-10204-8","article-title":"Left atrial structure and function in heart failure with reduced (HFrEF) versus preserved ejection fraction (HFpEF): Systematic review and meta-analysis","volume":"27","author":"Jin","year":"2022","journal-title":"Heart Fail. Rev."},{"key":"ref_3","doi-asserted-by":"crossref","unstructured":"Fauchier, L., Bisson, A., and Bodin, A. (2023). Heart failure with preserved ejection fraction and atrial fibrillation: Recent advances and open questions. BMC Med., 21.","DOI":"10.1186\/s12916-023-02764-3"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"1351","DOI":"10.1136\/heartjnl-2021-320131","article-title":"Prevalence, incidence and survival of heart failure: A systematic review","volume":"108","author":"Johnson","year":"2022","journal-title":"Heart"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1007\/s11897-021-00510-5","article-title":"Left Atrial Myopathy in Atrial Fibrillation and Heart Failure: Clinical Implications, Mechanisms, and Therapeutic Targets","volume":"18","author":"Peigh","year":"2021","journal-title":"Curr. Heart Fail. Rep."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"1212","DOI":"10.1253\/circj.CJ-20-0258","article-title":"Heart Failure in Atrial Fibrillation\u2014An Update on Clinical and Echocardiographic Implications","volume":"84","author":"Taniguchi","year":"2020","journal-title":"Circ. J."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"932","DOI":"10.1016\/j.jacc.2023.12.033","article-title":"Implications of Atrial Fibrillation for Guideline-Directed Therapy in Patients With Heart Failure: JACC State-of-the-Art Review","volume":"83","author":"Newman","year":"2024","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1007\/s11897-024-00691-9","article-title":"Atrial Fibrillation in Heart Failure: Novel Insights, Challenges, and Treatment Opportunities","volume":"22","author":"Bidaoui","year":"2024","journal-title":"Curr. Heart Fail. Rep."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.ccep.2024.08.006","article-title":"Atrial Fibrillation Ablation in Heart Failure with Preserved Ejection Fraction","volume":"17","author":"Pierucci","year":"2025","journal-title":"Card. Electrophysiol. Clin."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"1810","DOI":"10.1016\/j.jacc.2023.01.049","article-title":"Heart Failure With Preserved Ejection Fraction: JACC Scientific Statement","volume":"81","author":"Borlaug","year":"2023","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"H1267","DOI":"10.1152\/ajpheart.00121.2025","article-title":"Cardiac energy substrate utilization in heart failure with preserved ejection fraction: Reconciling conflicting evidence on fatty acid and glucose metabolism","volume":"328","author":"Shehadeh","year":"2025","journal-title":"Am. J. Physiol. Heart Circ. Physiol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"6644631","DOI":"10.1155\/2021\/6644631","article-title":"Myokines and Heart Failure: Challenging Role in Adverse Cardiac Remodeling, Myopathy, and Clinical Outcomes","volume":"2021","author":"Berezin","year":"2021","journal-title":"Dis. Markers"},{"key":"ref_13","doi-asserted-by":"crossref","unstructured":"Li, C., Qin, D., Hu, J., Yang, Y., Hu, D., and Yu, B. (2022). Inflamed adipose tissue: A culprit underlying obesity and heart failure with preserved ejection fraction. Front. Immunol., 13.","DOI":"10.3389\/fimmu.2022.947147"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"5657","DOI":"10.19102\/icrm.2023.14111","article-title":"Adipokines and Their Role in Heart Failure: A Literature Review","volume":"14","author":"Rafaqat","year":"2023","journal-title":"J. Innov. Card. Rhythm Manag."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1007\/s10557-020-07071-0","article-title":"Inflammatory Cytokines and Chemokines as Therapeutic Targets in Heart Failure","volume":"34","author":"Hanna","year":"2020","journal-title":"Cardiovasc. Drugs Ther."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/bs.apcsb.2023.12.021","article-title":"Diagnostic and predictive abilities of myokines in patients with heart failure","volume":"142","author":"Berezin","year":"2024","journal-title":"Adv. Protein Chem. Struct. Biol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"2327367","DOI":"10.1080\/13814788.2024.2327367","article-title":"Biomarkers for predicting atrial fibrillation: An explorative sub-analysis of the randomised SCREEN-AF trial","volume":"30","author":"Gladstone","year":"2024","journal-title":"Eur. J. Gen. Pract."},{"key":"ref_18","doi-asserted-by":"crossref","unstructured":"Demirel, O., Berezin, A.E., Mirna, M., Boxhammer, E., Gharibeh, S.X., Hoppe, U.C., and Lichtenauer, M. (2023). Biomarkers of Atrial Fibrillation Recurrence in Patients with Paroxysmal or Persistent Atrial Fibrillation Following External Direct Current Electrical Cardioversion. Biomedicines, 11.","DOI":"10.3390\/biomedicines11051452"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"2271","DOI":"10.1007\/s10554-024-03218-4","article-title":"Comprehensive analysis of recurrence factors in cryoballoon AF ablation: Integrating clinical, biomarkers, and echocardiographic parameters","volume":"40","author":"Soysal","year":"2024","journal-title":"Int. J. Cardiovasc. Imaging"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"2323","DOI":"10.1002\/ehf2.14799","article-title":"Identification of common mechanisms and biomarkers of atrial fibrillation and heart failure based on machine learning","volume":"11","author":"Zhang","year":"2024","journal-title":"ESC Heart Fail."},{"key":"ref_21","doi-asserted-by":"crossref","unstructured":"Ali, I.I., D\u2019Souza, C., Singh, J., and Adeghate, E. (2022). Adropin\u2019s Role in Energy Homeostasis and Metabolic Disorders. Int. J. Mol. Sci., 23.","DOI":"10.3390\/ijms23158318"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"e240117","DOI":"10.1530\/JOE-24-0117","article-title":"The levels of adropin and its therapeutic potential in diabetes","volume":"265","author":"Skrzypski","year":"2025","journal-title":"J. Endocrinol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1016\/j.cmet.2008.10.011","article-title":"Identification of adropin as a secreted factor linking dietary macronutrient intake with energy homeostasis and lipid metabolism","volume":"8","author":"Kumar","year":"2008","journal-title":"Cell Metab."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"13366","DOI":"10.1074\/jbc.RA119.008967","article-title":"The peptide hormone adropin regulates signal transduction pathways controlling hepatic glucose metabolism in a mouse model of diet-induced obesity","volume":"294","author":"Gao","year":"2019","journal-title":"J. Biol. Chem."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"110532","DOI":"10.1016\/j.mce.2019.110532","article-title":"Effects of adropin on proliferation and differentiation of 3T3-L1 cells and rat primary preadipocytes","volume":"496","author":"Jasaszwili","year":"2019","journal-title":"Mol. Cell. Endocrinol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"eadd6570","DOI":"10.1126\/scitranslmed.add6570","article-title":"Attenuation of fibroblast activation and fibrosis by adropin in systemic sclerosis","volume":"16","author":"Liang","year":"2024","journal-title":"Sci. Transl. Med."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"171391","DOI":"10.1016\/j.peptides.2025.171391","article-title":"Adropin: A cardio-metabolic hormone in the periphery, a neurohormone in the brain?","volume":"187","author":"Butler","year":"2025","journal-title":"Peptides"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"H879","DOI":"10.1152\/ajpheart.00385.2022","article-title":"Role of adropin in arterial stiffening associated with obesity and type 2 diabetes","volume":"323","author":"Jurrissen","year":"2022","journal-title":"Am. J. Physiol. Heart Circ. Physiol."},{"key":"ref_29","first-page":"e35166","article-title":"The Relationship Between Coronary Collateral Circulation and Serum Adropin Levels","volume":"15","author":"Vural","year":"2023","journal-title":"Cureus"},{"key":"ref_30","doi-asserted-by":"crossref","unstructured":"Berezin, A.A., Obradovic, Z., Berezina, T.A., Boxhammer, E., Lichtenauer, M., and Berezin, A.E. (2023). Cardiac Hepatopathy: New Perspectives on Old Problems through a Prism of Endogenous Metabolic Regulations by Hepatokines. Antioxidants, 12.","DOI":"10.3390\/antiox12020516"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"1394","DOI":"10.1038\/oby.2012.31","article-title":"Adropin deficiency is associated with increased adiposity and insulin resistance","volume":"20","author":"Zhang","year":"2012","journal-title":"Obesity"},{"key":"ref_32","doi-asserted-by":"crossref","unstructured":"Berezina, T.A., Berezin, O.O., Hoppe, U.C., Lichtenauer, M., and Berezin, A.E. (2024). Low Levels of Adropin Predict Adverse Clinical Outcomes in Outpatients with Newly Diagnosed Prediabetes after Acute Myocardial Infarction. Biomedicines, 12.","DOI":"10.3390\/biomedicines12081857"},{"key":"ref_33","first-page":"39","article-title":"Adropin and Irisin in Patients with Cardiac Cachexia","volume":"111","author":"Kalkan","year":"2018","journal-title":"Arq. Bras. Cardiol."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1089\/met.2021.0015","article-title":"Correlation of Serum Adropin Levels with Risk Factors of Cardiovascular Disease in Hemodialysis Patients","volume":"19","author":"Liu","year":"2021","journal-title":"Metab. Syndr. Relat. Disord."},{"key":"ref_35","first-page":"e32748","article-title":"Serum Adropin Level in the Early Period of ST-Elevation Myocardial Infarction and Its Relationship With Cobalamin and Folic Acid","volume":"14","author":"Kaya","year":"2022","journal-title":"Cureus"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1002\/jpn3.12423","article-title":"Serum adropin is unaltered in adolescents with histology-confirmed steatotic liver disease","volume":"80","author":"Bays","year":"2025","journal-title":"J. Pediatr. Gastroenterol. Nutr."},{"key":"ref_37","doi-asserted-by":"crossref","unstructured":"Berezina, T.A., Berezin, O.O., Hoppe, U.C., Lichtenauer, M., and Berezin, A.E. (2024). Adropin Predicts Asymptomatic Heart Failure in Patients with Type 2 Diabetes Mellitus Independent of the Levels of Natriuretic Peptides. Diagnostics, 14.","DOI":"10.3390\/diagnostics14161728"},{"key":"ref_38","doi-asserted-by":"crossref","unstructured":"El Moneem Elfedawy, M.A., El Sadek Elsebai, S.A., Tawfik, H.M., Youness, E.R., and Zaki, M. (2024). Adropin a candidate diagnostic biomarker for cardiovascular disease in patients with chronic kidney disease. J. Genet. Eng. Biotechnol., 22.","DOI":"10.1016\/j.jgeb.2024.100438"},{"key":"ref_39","doi-asserted-by":"crossref","unstructured":"Kaur, R., Krishan, P., Kumari, P., Singh, T., Singh, V., Singh, R., and Ahmad, S.F. (2023). Clinical Significance of Adropin and Afamin in Evaluating Renal Function and Cardiovascular Health in the Presence of CKD-MBD Biomarkers in Chronic Kidney Disease. Diagnostics, 13.","DOI":"10.3390\/diagnostics13193158"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1007\/s12325-024-03036-z","article-title":"Predictors for Irreversibility of Contrast-Induced Acute Kidney Injury in Patients with Obesity After Contrast-Enhanced Computed Tomography Coronary Angiography","volume":"42","author":"Berezina","year":"2025","journal-title":"Adv. Ther."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1002\/ejhf.2333","article-title":"2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: Developed by the Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). With the special contribution of the Heart Failure Association (HFA) of the ESC","volume":"24","author":"McDonagh","year":"2022","journal-title":"Eur. J. Heart Fail."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1093\/eurheartj\/ehaa612","article-title":"2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS): The Task Force for the diagnosis and management of atrial fibrillation of the European Society of Cardiology (ESC) Developed with the special contribution of the European Heart Rhythm Association (EHRA) of the ESC","volume":"42","author":"Hindricks","year":"2021","journal-title":"Eur. Heart J."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"e125","DOI":"10.1161\/CIR.0000000000000665","article-title":"2019 AHA\/ACC\/HRS Focused Update of the 2014 AHA\/ACC\/HRS Guideline for the Management of Patients With Atrial Fibrillation: A Report of the American College of Cardiology\/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society in Collaboration With the Society of Thoracic Surgeons","volume":"140","author":"January","year":"2019","journal-title":"Circulation"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.echo.2018.06.004","article-title":"Guidelines for Performing a Comprehensive Transthoracic Echocardiographic Examination in Adults: Recommendations from the American Society of Echocardiography","volume":"32","author":"Mitchell","year":"2018","journal-title":"J. Am. Soc. Echocardiogr."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"604","DOI":"10.7326\/0003-4819-150-9-200905050-00006","article-title":"CKD-EPI (Chronic Kidney Disease Epidemiology Collaboration). A new equation to estimate glomerular filtration rate","volume":"150","author":"Levey","year":"2009","journal-title":"Ann. Intern. Med."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1007\/BF00280883","article-title":"Homeostasis model assessment: Insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man","volume":"28","author":"Matthews","year":"1985","journal-title":"Diabetologia"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"1267","DOI":"10.1007\/s10554-020-02113-y","article-title":"Atrial conduction time associated predictors of recurrent atrial fibrillation","volume":"37","author":"Karantoumanis","year":"2021","journal-title":"Int. J. Cardiovasc. Imaging"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1016\/j.hrthm.2018.10.022","article-title":"Incidence and predictors of atrial fibrillation progression: A systematic review and meta-analysis","volume":"16","author":"Blum","year":"2019","journal-title":"Heart Rhythm"},{"key":"ref_49","doi-asserted-by":"crossref","unstructured":"Turkkolu, S.T., Sel\u00e7uk, E., and K\u00f6ksal, C. (2021). Biochemical predictors of postoperative atrial fibrillation following cardiac surgery. BMC Cardiovasc. Disord., 21.","DOI":"10.1186\/s12872-021-01981-z"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1159\/000527272","article-title":"Risk Factors for New Onset Atrial Fibrillation during Thyroid Gland Surgery","volume":"31","author":"Stojanovic","year":"2022","journal-title":"Med. Princ. Pract."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"e00927","DOI":"10.1002\/prp2.927","article-title":"Distinct atrial remodeling in patients with subclinical atrial fibrillation: Lessons from computed tomographic images","volume":"10","author":"Huang","year":"2022","journal-title":"Pharmacol. Res. Perspect."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1002\/ehf2.13703","article-title":"NT-proBNP as a marker for atrial fibrillation and heart failure in four observational outpatient trials","volume":"9","author":"Werhahn","year":"2022","journal-title":"ESC Heart Fail."},{"key":"ref_53","doi-asserted-by":"crossref","unstructured":"Staszewsky, L., Meessen, J.M.T.A., Novelli, D., Wienhues-Thelen, U.H., Disertori, M., Maggioni, A.P., Masson, S., Tognoni, G., Franzosi, M.G., and Lucci, D. (2021). Total NT-proBNP, a novel biomarker related to recurrent atrial fibrillation. BMC Cardiovasc. Disord., 21.","DOI":"10.1186\/s12872-021-02358-y"},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/j.ajem.2023.05.041","article-title":"NT-proBNP cut-off value for ruling out heart failure in atrial fibrillation patients\u2014A prospective clinical study","volume":"71","author":"Budolfsen","year":"2023","journal-title":"Am. J. Emerg. Med."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1186\/s12933-023-01913-5","article-title":"Obesity and atrial fibrillation: A narrative review from arrhythmogenic mechanisms to clinical significance","volume":"22","author":"Shu","year":"2023","journal-title":"Cardiovasc. Diabetol."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/j.ijcard.2016.08.001","article-title":"NT-proBNP is a powerful predictor for incident atrial fibrillation\u2014Validation of a multimarker approach","volume":"223","author":"Svennberg","year":"2016","journal-title":"Int. J. Cardiol."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1136\/heartjnl-2024-324685","article-title":"Association between NT-proBNP levels and risk of atrial fibrillation: A systematic review and meta-analysis of cohort studies","volume":"111","author":"Wangm","year":"2025","journal-title":"Heart"},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"e22672","DOI":"10.1002\/jcla.22672","article-title":"Association of serum adropin with the presence of atrial fibrillation and atrial remodeling","volume":"33","author":"Wang","year":"2019","journal-title":"J. Clin. Lab. Anal."},{"key":"ref_59","doi-asserted-by":"crossref","unstructured":"Berezin, A.A., Obradovic, Z., Fushtey, I.M., Berezina, T.A., Novikov, E.V., Schmidbauer, L., Lichtenauer, M., and Berezin, A.E. (2023). The Impact of SGLT2 Inhibitor Dapagliflozin on Adropin Serum Levels in Men and Women with Type 2 Diabetes Mellitus and Chronic Heart Failure. Biomedicines, 11.","DOI":"10.3390\/biomedicines11020457"},{"key":"ref_60","doi-asserted-by":"crossref","unstructured":"Wang, J., Ding, N., Chen, C., Gu, S., Liu, J., Wang, Y., Lin, L., Zheng, Y., and Li, Y. (2025). Adropin: A key player in immune cell homeostasis and regulation of inflammation in several diseases. Front. Immunol., 16.","DOI":"10.3389\/fimmu.2025.1482308"},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"3242","DOI":"10.2337\/db14-0388","article-title":"Regulation of substrate oxidation preferences in muscle by the peptide hormone adropin","volume":"63","author":"Gao","year":"2014","journal-title":"Diabetes"},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1038\/s41420-023-01697-3","article-title":"Adropin inhibits the progression of atherosclerosis in ApoE-\/-\/Enho-\/- mice by regulating endothelial-to-mesenchymal transition","volume":"9","author":"Ying","year":"2023","journal-title":"Cell Death Discov."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"37330","DOI":"10.1021\/acsami.2c06957","article-title":"Adropin Carried by Reactive Oxygen Species-Responsive Nanocapsules Ameliorates Renal Lipid Toxicity in Diabetic Mice","volume":"14","author":"Yu","year":"2022","journal-title":"ACS Appl. Mater. Interfaces"}],"container-title":["Biomolecules"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2218-273X\/15\/8\/1171\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T18:28:27Z","timestamp":1760034507000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2218-273X\/15\/8\/1171"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,15]]},"references-count":63,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2025,8]]}},"alternative-id":["biom15081171"],"URL":"https:\/\/doi.org\/10.3390\/biom15081171","relation":{},"ISSN":["2218-273X"],"issn-type":[{"value":"2218-273X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,15]]}}}